Evidence map›Paper›PMID 30286808›Full record

ReviewStem cell research & therapy2018

The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure.

Yantao He, Dongmei Chen, Lingling Yang, Qiaoni Hou, Huiming Ma, Xian Xu

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04444245 (Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density), which is not on this map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04444245 phase1unknown statusnot on this mapstarted 2022, after this paper: background citation

Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection

TypeinterventionalSponsorBlack Tie Medical, Inc.Ran2022 to 2025Enrolled100ConditionsOvarian Failure, Perimenopausal Disorder, Hormone DisturbanceArmslipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 153 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yantao HeKey Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan, 750004, Ningxia, China.
Dongmei ChenInstitute of human stem cells research of General Hospital of Ningxia Medical University, Ningxia Medical University, No. 804 Shengli Street, Yinchuan, 750004, Ningxia, China.
Lingling YangKey Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan, 750004, Ningxia, China.
Qiaoni HouKey Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan, 750004, Ningxia, China.
Huiming MaKey Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan, 750004, Ningxia, China. mhm289@hotmail.com.
Xian XuKey Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan, 750004, Ningxia, China. xux36@163.com.
Ningxia Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of regenerative medicine, a variety of mesenchymal stem cells (MSCs) are increasingly considered for the treatment of premature ovarian failure (POF). Reportedly, bone marrow-derived MSCs (BMSCs) improve the ovarian reserve, which mainly depends on homing and paracrine activities. Furthermore, paracrine factors secreted by these stem cells play an important role in ovarian recovery. Relevant studies indicate that BMSC transplantation has some positive effects on the treatment of POF in animals, but BMSCs are not widely applied in clinical therapy. Clinical trials are ongoing despite the fact that several patients experiencing BMSC transplantation recover their normal menstrual cycles and even give birth to babies. In this review, we discuss the possible therapeutic mechanisms of BMSCs for POF, migration, antiapoptosis, antifibrosis, angiogenesis, anti-inflammation, immunoregulation, and oxidative stress, which provide the theoretical basis for further study and clinical therapy.

Indexed as

Mesenchymal Stem Cell TransplantationNeovascularization, PhysiologicAnimalsBone Marrow CellsCell MovementCytokinesFemaleHumansIntercellular Signaling Peptides and ProteinsMenstrual CycleMesenchymal Stem CellsOvaryParacrine CommunicationPrimary Ovarian InsufficiencyRegenerative MedicineCytokinesIntercellular Signaling Peptides and ProteinsBone marrow mesenchymal stem cellsPremature ovarian failureTransplantation

Identifiers

PMID30286808
PMCPMC6172726
OpenAlexW2894663353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.